Treatment of hepatitis C: Current standard and future concepts;Therapie der hepatitis C: Aktuelle standards und zukünftige entwicklungen

Chemotherapie Journal

Volumn 21, Issue 1, 2012, Pages 1-7

  Wedemeyer, Heiner ^a   Hardtke, Svenja ^a   Cornberg, Markus ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Genotype; HCV; Hepatitis c infection; IL28b; Interferon alfa; Protease inhibitor; Ribavirin

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BOCEPREVIR; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR;

CHRONIC DISEASE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; REVIEW; TREATMENT RESPONSE; VIRUS HEPATITIS;

EID: 84857244174     PISSN: 09406735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Abid K, Pazienza V, de Gottardi A, Rubbia-Brandt L, et al. An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J Hepatology 2005;42:744-51.
2. Alberti A. The global health burden of hepatitis C virus infection. Liver Int 2011;31(Suppl 2):1-3.
3. Antaki N, Craxi A, Kamal S, Moucari R, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010;30:342-55.
4. Backus LI, Boothroyd DB, Phillips BR, Belperio P, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011;9:509-516.e1.
5. Bacon BR, Gordon SC, Lawitz E, Marcellin P, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
6. Bochud PY, Cai T, Overbeck K, Bochud M, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009;51:655-66.
7. Bodenheimer HC, Lindsay KL, Davis GL, Lewis JH, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 1997;26:473-7. (Pubitemid 27328328)
8. Boffetta P, Castaing M, Brennan P. A geographic correlation study of the incidence of pancreatic and other cancers in whites. Eur J Epidemiol 2006;21:39-46. (Pubitemid 43188729)
9. Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52:652-7.
10. Choo QL, Kuo G, Weiner AJ, Overby LR, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62. (Pubitemid 19117877)
11. Cornberg M. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31:30-60.
12. Cornberg M, Deterding K, Manns MP. Present and future therapy for hepatitis C virus. Expert Rev Anti Infect Ther 2006;4:781-93. (Pubitemid 44890618)
13. Cornberg M, Wedemeyer H, Manns MP. Treatment of chronic hepatitis C with pegylated interferon and ribavirin. Curr Gastroenterol Rep 2002;4:23-30.
14. Deterding K, Wiegand J, Gruner N, Hahn A, et al. The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. Z Gastroenterol 2009;47:531-40.
15. Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, et al. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology 2011;53:1100-8.
16. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011;54:396-405.
17. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008;48:148-62. (Pubitemid 350191999)
18. Fried MW, Shiffman ML, Reddy KR, Smith C, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
19. Ge DL, Fellay J, Thompson AJ, Simon JS, et al. Genetic variation in IL28b predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
20. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, et al. Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-8. (Pubitemid 36799109)
21. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management and treatment of hepatitis C: An update. Hepatology 2009;49:1335-74.
22. Hartmann D, Srivastava U, Thaler M, Kleinhans KN, et al. Telomerase gene mutations are associated with cirrhosis formation. Hepatology 2011;53:1608-17.
23. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002;36:S21-9. (Pubitemid 35253460)
24. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. Clin Gastroenterol Hepatol 2005;3:1150-9. (Pubitemid 41565383)
25. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
26. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-7.
27. Kamal SM, Ismail A, Graham CS, He Q, et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004;39:1721-31. (Pubitemid 38702674)
28. Kamal SM, Nasser IA. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology 2008;47:1371-83. (Pubitemid 351547923)
29. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107-15.
30. Lechel A, Manns MP, Rudolph KL. Telomeres and telomerase: new targets for the treatment of liver cirrhosis and hepatocellular carcinoma. J Hepatol 2004;41:491-7. (Pubitemid 39158760)
31. th EASL Congress, Berlin, 2011. J Hepatol 2011; 54(Suppl 1):S536(Abstract 1356).
32. Malcolm BA, Liu R, Lahser F, Agrawal S, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006;50:1013-20. (Pubitemid 43327807)
33. Manns M, Zeuzem S, Sood A, Lurie Y, et al. Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. J Hepatol 2011;55:554-63.
34. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, et al. The way forward in HCV treatment - finding the right path. Nat Rev Drug Discov 2007;6:991-1000. (Pubitemid 350201789)
35. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65. (Pubitemid 32913521)
36. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: Efficacy, side effects, and complications. Gut 2006;55:1350-9. (Pubitemid 44277369)
37. McHutchison J, Blatt L, Sedghi-Vaziri A, Russell J, et al. Is there an optimal time to measure quantitative HCV-RNA to predict non-response following interferon treatment for chronic HCV infection? J Hepatol 1998;29:362-8. (Pubitemid 28396651)
38. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006;13:34-41.
39. Mikkelsen M, Holst PJ, Bukh J, Thomsen AR, et al. Enhanced and sustained CD8(+) T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain. J Immunol 2011;186:2355-64.
40. Ohata K, Hamasaki K, Toriyama K, Matsumoto K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003;97:3036-43. (Pubitemid 36676258)
41. Perni RB, Almquist SJ, Byrn RA, Chandorkar G, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006;50:899-909. (Pubitemid 43327793)
42. Peters M, Davis GL, Dooley JS, Hoofhagle JH. The interferon system in acute and chronic viral hepatitis. Prog Liver Dis 1986;8:453-67.
43. Poordad F, McCone J, Bacon BR, Bruno S, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
44. Poynard T, Leroy V, Cohard M, Thevenot T, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89. (Pubitemid 26334273)
45. Poynard T, Marcellin P, Lee SS, Niederau C, et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-32. (Pubitemid 28510876)
46. Ratziu V, Heurtier A, Bonyhay L, Poynard T, et al. Review article: an unexpected virus-host interaction - the hepatitis C virus-diabetes link. Aliment Pharmacol Ther 2005;22(Suppl 2):56-60. (Pubitemid 41564385)
47. Rauch A, Kutalik Z, Descombes P, Cai T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-45.
48. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33:106-15. (Pubitemid 30418941)
49. Sarrazin C, Berg T, Ross RS, Schirmacher P, et al. Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: The German guidelines on the management of HCV infection. Z Gastroenterol 2010;48:289-351.
50. Sherman KE. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-24.
51. Shiffman ML, Hubbard SB, Long A, Contos MJ, et al. The long term effects of interferon based (IFNTx) therapy on hepatic histology in patients with chronic hepatitis C virus. Results of a five year prospective evaluation on fibrosis progression and fibrosis regression. Gastroenterology 2009;136(Suppl 1):A790.
52. Simmonds P, Bukh J, Combet C, Deleage G, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962-73. (Pubitemid 41401136)
53. Stepanova M, Rafiq N, Younossi ZM. Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study. Gut 2010;59:1410-5.
54. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4.
55. Tagger A, Donato F, Ribero ML, Chiesa R, et al. Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study. Int J Cancer 1999;81:695-9. (Pubitemid 29214375)
56. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9.
57. Thomas DL, Thio CL, Martin MP, Qi Y, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
58. Thomas E, Feld JJ, Li QS, Hu ZY, et al. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011;53:32-41.
59. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139:120-9.
60. Tillmann HL, Thompson AJ, Patel K, Wiese M, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010;139:1586-92.
61. Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol 2011;54:1273-85.
62. van de Laar TJW, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS 2010;24:1799-812.
63. Veldt BJ, Chen WD, Heathcote EJ, Wedemeyer H, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008;47:1856-62. (Pubitemid 351945553)
64. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Int Med 2007;147:677-84. (Pubitemid 351664462)
65. Wedemeyer H, Jaeckel E. Ist eine Kombinationstherapie der chronischen Hepatitis C mit Interferon alpha und Ribavirin bei primären Interferon-Nonrespondern indiziert? Eine Analyse der eigenen Erfahrungen und eine Zusammenfassung der Literatur. Z Gastroenterol 1998;36:819-27. (Pubitemid 28452585)
66. Wedemeyer H, Wiegand J, Cornberg M, Manns MP. Polyethylene glycol-interferon: Current status in hepatitis C virus therapy. J Gastroenterol Hepatol 2002;17(Suppl 3):S344-50. (Pubitemid 35454309)
67. Wiegand J, Buggisch P, Boecher W, Zeuzem S, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acuteHCV-II study. Hepatology. 2006;43:250-6.
68. Zeuzem S, Andreone P, Pol S, Lawitz E, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.